Topics

AstraZeneca strikes global commercial rights deal for $243m

05:11 EDT 2 Oct 2019 | Pharmafile

Cambridge-headquartered AstraZeneca have agreed to sell certain global commercial rights for its Losec brand, in a deal that is worth around $243 million.

Losec is a proton pump inhibitor discovered and developed by AstraZeneca. It assists in reducing the amount of acid produced by the stomach in patients with gastrointestinal reflux conditions and ulcers.

The divestment also includes medications containing omeprazole marketed by AstraZeneca under the Acimax, Antra, Mepral, Mopral, Omepral and Zoltum medicine names.

read more

Original Article: AstraZeneca strikes global commercial rights deal for $243m

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca strikes global commercial rights deal for $243m"

Quick Search

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...